Bajaj Healthcare Ltd · NSE:BAJAJHCARE
Bajaj Healthcare — Investor Presentation (December 2025)
20 slides from Bajaj Healthcare's investor presentation, December 2025
Slide 1: Bajaj Healthcare Limited
Bajaj Healthcare Limited Your Trusted Associate in Pharmaceuticals & Healthcare Industry
Slide 2: Company Overview
Company Overview
Slide 3: Bajaj Healthcare | At Glance
Bajaj Healthcare | At Glance More than 3 decades of World’s Major India’s Major Private Player manufacturing expertise Undertaking the Alkaloid Extraction Manufacturer of Manufacturer of Ascorbic Acid work for the Government of India Chlorhexidine base 100+ 1,500+ 20 100 Products manufactured across
Slide 4: Executive Directors
Executive Directors Mr. Sajankumar R. Bajaj Ms. Namrata S. Bajaj Chairman & Managing Director Whole Time Director o Self-Driven, dedicated and hard-working leader with over 35+ years o Bachelors in Business Administration from Indian Institution of of industry experience Planning and Management, Mum
Slide 5: Management Team
Management Team Mr. Rajesh Desai Mr. Amit Rajan Financial Advisor Chief Technical Officer o He brings with him over 37 years of rich and diverse experience across o He has over 22 years of global experience in regulatory advisory and Finance and Legal domains. He has worked with Glenmark quality ass
Slide 6: Management Team
Management Team Mr. AG Prasad Mr. Byju T Executive Vice President, Sales & Marketing Vice President, Technical Head o He is an accomplished pharmaceutical sales and marketing leader with 38 o Mr. Byju brings us 26 years of diversified experience in Pharma years of proven experience. He has worked wi
Slide 7: About BHL
About BHL 01 02 03 04 Background Product Line & capacity Alkaloid Processing CDMO Business • Commenced operation in the Year • 730 MT per month of Active • BHCL is the private player who has • Entered into CDMO Agreement for 1993, headquartered at Thane, Pharmaceutical Ingredients (APIs) been awarde
Slide 8: Our Vision and Mission
Our Vision and Mission VISION VALUES • Our vision is to be a leading pharmaceutical company in India and to become a significant global player by providing high quality and affordable products. • Commitment to continuous improvement and innovation. • To develop environment friendly system. • Contrib
Slide 9: Key Milestones
Key Milestones Successfully Incorporation of commissioned the the company and Acquired Acquired Intermediate Alkaloid Extraction establishment of Acquired 2nd API Formulation Unit Acquired a Unit at Tarapur, Company migrated Plant in Vadodara, 1st API plant at unit at Tarapur, at Manjusar, formulati
Slide 10: Our capabilities
Our capabilities
Slide 11: Business Verticals
Business Verticals Active Pharmaceutical Ingredients (APIs) & Intermediates CDMO ▪ Provide high-quality and high value APIs in key therapeutic categories. ▪ Focus on producing APIs with Backward Integration. ▪ The Company has entered into a definitive CDMO ▪ Focus on introduction of cutting-edge rev
Slide 12: Bajaj Oncocare
Bajaj Oncocare Bajaj Oncocare – a dedicated oncology division of Bajaj Healthcare delivering affordable, quality cancer care. Focused portfolio across solid tumors, hematological cancers, and supportive care. First in India to launch Posaconazole 300 mg, reducing pill burden and improving compliance
Slide 13: Peptide Synthesis
Peptide Synthesis • We are constructing a state-of-the-art peptide manufacturing plant, which is scheduled for commercializing by March 2026. The plant will have an installed capacity of approximately 250 kg per annum, enabling the company to meet both domestic and international demand. • We have al
Slide 14: Our Facilities | Certification And Accreditations
Our Facilities | Certification And Accreditations API Unit in Savli, API and Intermediate units in API Unit in Panoli, Formulation Unit, GJ Tarapur MH GJ Manjusar, GJ and Nashik MH o USFDA approved o CEP certificate for Chlorhexidine Digluconate o GMP certification by the state FDA for the o WHO-GMP
Slide 15: In-House R&D Center
In-House R&D Center IMAGE IMAGE ▪ We have a DSIR-approved R&D facility located within our manufacturing site at Savli, Vadodara, Gujarat. ▪ Our team consists of more than 50 experienced experts with extensive hands-on knowledge in research and development. ▪ Within our R&D centre, we focus on new pr
Slide 16: Revenue Mix
Revenue Mix 24% 23% Domestic 36% HYE FY24 FY25 Sept 25 Exports 64% 76% 77% 11% 17% 16% API HYE FY24 FY25 Sept 25 Formulations 89% 83% 84% 16
Slide 17: Financials
Financials
Slide 18: Profitability Statement
Profitability Statement Rs in Cr. HYE Particulars FY 2023 FY 2024 FY 2025 Sept 2025 Total Income 647.38 482.10 562.01 299.28 Gross Contribution 264.59 227.33 275.56 145.09 EBITDA 112.95 84.95 101.83 53.99 PBT from Continuing Operations 78.19 27.65 46.01 30.49 Exceptional Item - (44.33) - - Tax expen
Slide 19: Balance Sheet
Balance Sheet Rs in Cr. Particulars FY 2023 FY 2024 FY 2025 Sept 2025 Current Assets 509.74 404.54 485.40 472.88 Current Liabilities 115.39 108.60 114.31 105.08 Net Working Capital 394.35 295.94 371.09 367.80 Net Fixed Assets & CWIP 387.40 259.37 241.90 257.02 Other Long Term Assets 4.30 101.20 105.
Slide 20: THANK YOU
For further information, please contact: Company : Bajaj Healthcare Limited CIN: L99999MH1993PLC072892 Address: 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) 400 604 THANK YOU
Bajaj Healthcare — Investor Presentation (December 2025) on 6ix